{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:49:26Z","timestamp":1791910166534,"version":"4.3.4"},"reference-count":152,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.gim.2024.101243","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:18:39Z","timestamp":1733357919000},"page":"101243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)"],"prefix":"10.1016","volume":"27","author":[{"given":"Tuya","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Schon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Astiazaran-Symonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Klugman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia A.","family":"Livinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Ngeow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta","family":"Voian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra J.","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6199","key":"10.1016\/j.gim.2024.101243_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/336577a0","article-title":"Localization of an ataxia-telangiectasia gene to chromosome 11q22-23","volume":"336","author":"Gatti","year":"1988","journal-title":"Nature"},{"issue":"5218","key":"10.1016\/j.gim.2024.101243_bib2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.7792600","article-title":"A\u00a0single ataxia telangiectasia gene with a product similar to PI-3 kinase","volume":"268","author":"Savitsky","year":"1995","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1542\/peds.21.4.526","article-title":"Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection","volume":"21","author":"Boder","year":"1958","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib4","first-page":"89","article-title":"Mortality and cancer incidence in 263 patients with ataxia-telangiectasia","volume":"77","author":"Morrell","year":"1986","journal-title":"J Natl Cancer Inst"},{"issue":"7344","key":"10.1016\/j.gim.2024.101243_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(64)91209-7","article-title":"Ataxia-telangiectasia. Its association with a defective thymus, immunological-deficiency disease, and malignancy","volume":"1","author":"Peterson","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.gim.2024.101243_bib6","first-page":"115","article-title":"Genetic aspects of ataxia telangiectasia","volume":"61","author":"Swift","year":"1993","journal-title":"Adv Neurol"},{"issue":"21","key":"10.1016\/j.gim.2024.101243_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","article-title":"Breast and other cancers in families with ataxia-telangiectasia","volume":"316","author":"Swift","year":"1987","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2013 association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A\u00a0population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib11","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr2919","article-title":"Rare variants in the ATM gene and risk of breast cancer","volume":"13","author":"Goldgar","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"11","key":"10.1016\/j.gim.2024.101243_bib12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/humu.20415","article-title":"Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry","volume":"27","author":"Bernstein","year":"2006","journal-title":"Hum Mutat"},{"issue":"15","key":"10.1016\/j.gim.2024.101243_bib13","first-page":"3480","article-title":"Seventh International Workshop on Ataxia-Telangiectasia","volume":"58","author":"Uhrhammer","year":"1998","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1086\/301673","article-title":"Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations","volume":"62","author":"Telatar","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib15","first-page":"573","article-title":"The incidence and gene frequency of ataxia-telangiectasia in the United States","volume":"39","author":"Swift","year":"1986","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/cge.14148","article-title":"Carrier frequency of autosomal recessive genetic conditions in diverse populations: lessons learned from the genome aggregation database","volume":"102","author":"Schmitz","year":"2022","journal-title":"Clin Genet"},{"issue":"7809","key":"10.1016\/j.gim.2024.101243_bib17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-020-2287-8","article-title":"A\u00a0structural variation reference for medical and population genetics","volume":"581","author":"Collins","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.gim.2024.101243_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.gim.2024.101243_bib20","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41436-020-0920-4","article-title":"Considerations in assessing germline variant pathogenicity using cosegregation analysis","volume":"22","author":"Belman","year":"2020","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.101036","article-title":"Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance\/Risk Allele Working Group","volume":"26","author":"Schmidt","year":"2024","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/clinchem\/hvaa250","article-title":"A\u00a0collaborative effort to define classification criteria for ATM variants in hereditary cancer patients","volume":"67","author":"Feliubadal\u00f3","year":"2021","journal-title":"Clin Chem"},{"issue":"7809","key":"10.1016\/j.gim.2024.101243_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib25","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/ijc.31921","article-title":"Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing","volume":"144","author":"Girard","year":"2019","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.gim.2024.101243_bib26","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/gcc.20381","article-title":"Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling","volume":"45","author":"Waddell","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-020-07749-6","article-title":"The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis","volume":"21","author":"Moslemi","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1086\/301706","article-title":"ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer","volume":"62","author":"Stankovic","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"database issue","key":"10.1016\/j.gim.2024.101243_bib29","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmedgenet-2018-105872","article-title":"Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report","volume":"56","author":"Spurdle","year":"2019","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-022-01052-8","article-title":"Breast cancer risks associated with missense variants in breast cancer susceptibility genes","volume":"14","author":"Dorling","year":"2022","journal-title":"Genome Med"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ijc.34305","article-title":"ATM c.7570G>C is a high-risk allele for breast cancer","volume":"152","author":"Kankuri-Tammilehto","year":"2023","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-020-01554-6","article-title":"Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers","volume":"39","author":"Federici","year":"2020","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.gim.2024.101243_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cancergen.2022.03.003","article-title":"Functional analysis of ATM variants in a high risk cohort provides insight into missing heritability","volume":"264-265","author":"Baughan","year":"2022","journal-title":"Cancer Genet"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104468","article-title":"Next step in molecular genetics of hereditary breast\/ovarian cancer: multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance","volume":"65","author":"Castillo-Guardiola","year":"2022","journal-title":"Eur J Med Genet"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41436-019-0478-1","article-title":"Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"Deignan","year":"2019","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41431-018-0285-1","article-title":"Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics","volume":"27","author":"Carrieri","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"10.1016\/j.gim.2024.101243_bib38","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.gim.2022.05.002","article-title":"Reclassification of clinically detected sequence variants: framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)","volume":"24","author":"Loong","year":"2022","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.gim.2024.101243_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/jnci\/dji141","article-title":"Cancer risks and mortality in heterozygous ATM mutation carriers","volume":"97","author":"Thompson","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.gim.2024.101243_bib41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajhg.2023.02.003","article-title":"The impact of coding germline variants on contralateral breast cancer risk and survival","volume":"110","author":"Morra","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"13","key":"10.1016\/j.gim.2024.101243_bib43","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.3390\/cancers14133292","article-title":"Prevalence of cancer predisposition germline variants in male breast cancer patients: results of the German Consortium for Hereditary Breast and Ovarian Cancer","volume":"14","author":"Rolfes","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-018-4661-x","article-title":"Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer","volume":"169","author":"Fostira","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"5924","key":"10.1016\/j.gim.2024.101243_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-11-0194","article-title":"ATM mutations in patients with hereditary pancreatic cancer","volume":"2","author":"Roberts","year":"2012","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00535-021-01806-y","article-title":"A\u00a0systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer","volume":"56","author":"Astiazaran-Symonds","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"issue":"11","key":"10.1016\/j.gim.2024.101243_bib49","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jamaoncol.2021.3701","article-title":"Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene","volume":"7","author":"Hsu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.gim.2024.101243_bib50","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.gim.2024.101243_bib51","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/jnci\/djac069","article-title":"Pancreatic ductal carcinoma risk associated with hereditary cancer-risk genes","volume":"114","author":"Gardiner","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib52","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamaoncol.2022.0373","article-title":"Association of pathogenic variants in hereditary cancer genes with multiple diseases","volume":"8","author":"Zeng","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib53","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib55","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/ijc.33024","article-title":"Rare germline genetic variants and risk of aggressive prostate cancer","volume":"147","author":"Nguyen-Dumont","year":"2020","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL Consortium Study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib57","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jnci\/djaa132","article-title":"Germline sequencing DNA repair genes in 5545 men with aggressive and nonaggressive prostate cancer","volume":"113","author":"Darst","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.gim.2024.101243_bib58","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.gim.2024.101243_bib59","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa2211807","article-title":"Helicobacter pylori, homologous-recombination genes, and gastric cancer","volume":"388","author":"Usui","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.gim.2024.101243_bib60","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8501","article-title":"Association of a polygenic risk score with breast cancer among women carriers of high- and moderate-risk breast cancer genes","volume":"3","author":"Gallagher","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.gim.2024.101243_bib61","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.20.01992","article-title":"Risk of breast cancer among carriers of pathogenic variants in breast cancer predisposition genes varies by polygenic risk score","volume":"39","author":"Gao","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.gim.2024.101243_bib62","article-title":"Comprehensive breast cancer risk assessment for CHEK2 and ATM pathogenic variant carriers incorporating a polygenic risk score and the Tyrer-Cuzick model","volume":"5","author":"Gallagher","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/jmg-2022-108502","article-title":"Clinical applicability of the polygenic risk score for breast cancer risk prediction in familial cases","volume":"60","author":"Lakeman","year":"2023","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.gim.2024.101243_bib64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2022.11.007","article-title":"Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease","volume":"179","author":"Jiao","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2021.04.013","article-title":"Combined effect of a polygenic risk score and rare genetic variants on prostate cancer risk","volume":"80","author":"Darst","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib66","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41391-021-00458-6","article-title":"Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies","volume":"25","author":"Xu","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib67","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/sj.bjc.6601549","article-title":"Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers","volume":"90","author":"Fernet","year":"2004","journal-title":"Br J Cancer"},{"issue":"32","key":"10.1016\/j.gim.2024.101243_bib68","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1038\/sj.onc.1204589","article-title":"Radiation induces genomic instability and mammary ductal dysplasia in Atm heterozygous mice","volume":"20","author":"Weil","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1520-6823(1999)7:4<231::AID-ROI4>3.0.CO;2-S","article-title":"Enhanced radiation late effects and cellular radiation sensitivity in an ATM heterozygous breast cancer patient","volume":"7","author":"Varghese","year":"1999","journal-title":"Radiat Oncol Investig"},{"issue":"18","key":"10.1016\/j.gim.2024.101243_bib70","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1001\/jama.286.18.2233-a","article-title":"Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations","volume":"286","author":"Su","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2003.08.004","article-title":"Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects","volume":"69","author":"Bremer","year":"2003","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib72","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.radonc.2004.07.010","article-title":"Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy","volume":"72","author":"Meyer","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.gim.2024.101243_bib73","article-title":"Tolerability of breast radiotherapy among carriers of ATM germline variants","volume":"5","author":"Modlin","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.gim.2024.101243_bib74","first-page":"299","article-title":"Breast cancer adjuvant radiotherapy in BRCA1\/2, TP53, ATM genes mutations: are there solved issues?","volume":"13","author":"Lazzari","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6744","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Breast Cancer Association Consortium","year":"2022","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.gim.2024.101243_bib76","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.gim.2024.101243_bib77","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jnci\/djaa040","article-title":"Contribution of germline predisposition gene mutations to breast cancer risk in African American women","volume":"112","author":"Palmer","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.gim.2024.101243_bib78","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.gim.2022.03.015","article-title":"Evaluating breast cancer predisposition genes in women of African ancestry","volume":"24","author":"D\u00edaz-Zabala","year":"2022","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib79","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1158\/1055-9965.EPI-21-1397","article-title":"Breast cancer risk in women from Ghana carrying rare germline pathogenic mutations","volume":"31","author":"Ahearn","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.gim.2024.101243_bib80","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djy028","article-title":"The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers","volume":"110","author":"Weigelt","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.gim.2024.101243_bib81","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A\u00a0mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.gim.2024.101243_bib82","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdz132","article-title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","volume":"30","author":"Nones","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib83","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/genes12050616","article-title":"Clinicopathologic profile of breast cancer in germline ATM and CHEK2 mutation carriers","volume":"12","author":"Toss","year":"2021","journal-title":"Genes (Basel)"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib84","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/MPA.0000000000001136","article-title":"Germline variants and risk for pancreatic cancer: a systematic review and emerging concepts","volume":"47","author":"Zhan","year":"2018","journal-title":"Pancreas"},{"issue":"10","key":"10.1016\/j.gim.2024.101243_bib85","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"21","key":"10.1016\/j.gim.2024.101243_bib86","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1158\/1078-0432.CCR-22-1483","article-title":"Clinico-genomic characterization of ATM and HRD in pancreas cancer: application for practice","volume":"28","author":"Park","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.gim.2024.101243_bib87","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.gim.2024.101243_bib88","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.gim.2024.101243_bib89","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1158\/1078-0432.CCR-20-0764","article-title":"Genomic and clinicopathologic characterization of ATM-deficient prostate cancer","volume":"26","author":"Kaur","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.gim.2024.101243_bib90","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cam4.4778","article-title":"Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance","volume":"11","author":"Brady","year":"2022","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jnci\/djz124","article-title":"Germline pathogenic variants in 7636 Japanese patients with prostate cancer and 12 366 controls","volume":"112","author":"Momozawa","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.gim.2024.101243_bib92","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/ijc.33272","article-title":"Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland","volume":"147","author":"Woko\u0142orczyk","year":"2020","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euo.2019.12.003","article-title":"Rare germline pathogenic mutations of DNA repair genes are most strongly associated with Grade group 5 prostate cancer","volume":"3","author":"Wu","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib94","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib95","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan","year":"2021","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib96","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1078-0432.CCR-20-3708","article-title":"BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression","volume":"27","author":"Warner","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.gim.2024.101243_bib97","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/pros.24374","article-title":"DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries","volume":"82","author":"Abdi","year":"2022","journal-title":"Prostate"},{"issue":"23","key":"10.1016\/j.gim.2024.101243_bib98","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152789","article-title":"Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer","volume":"6","author":"De Sarkar","year":"2021","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib99","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijrobp.2021.09.026","article-title":"Breast radiation therapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing","volume":"112","author":"Chapman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib102","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib103","doi-asserted-by":"crossref","first-page":"54","DOI":"10.6004\/jnccn.2021.7010","article-title":"Inherited mutations in Chinese men with prostate cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib104","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pros.24252","article-title":"Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: a meta-analysis","volume":"82","author":"Shi","year":"2022","journal-title":"Prostate"},{"issue":"16","key":"10.1016\/j.gim.2024.101243_bib105","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pros.24236","article-title":"Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations","volume":"81","author":"Sokolova","year":"2021","journal-title":"Prostate"},{"issue":"13","key":"10.1016\/j.gim.2024.101243_bib106","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.18.01512","article-title":"Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance","volume":"37","author":"Abe","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib107","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-19-0224","article-title":"Germline DNA sequencing reveals novel mutations predictive of overall survival in a cohort of patients with pancreatic cancer","volume":"26","author":"Goldstein","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.gim.2024.101243_bib108","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-20-1788","article-title":"Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma","volume":"26","author":"Yadav","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.gim.2024.101243_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104350","article-title":"Extended ERN-GENTURIS Thematic Group 3. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe","volume":"64","author":"Marmolejo","year":"2021","journal-title":"Eur J Med Genet"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol"},{"issue":"28","key":"10.1016\/j.gim.2024.101243_bib111","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.22.00298","article-title":"The multicenter cancer of pancreas screening study: impact on stage and survival","volume":"40","author":"Dbouk","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib112","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2020-323611","article-title":"Long-term yield of pancreatic cancer surveillance in high-risk individuals","volume":"71","author":"Overbeek","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","article-title":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","volume":"69","author":"Goggins","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib154","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.gie.2021.12.001","article-title":"ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations","volume":"95","author":"Sawhney","year":"2022","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gim.2024.101243_bib114","unstructured":"Daly MB, Pal T, AlHilli Z, et al. NCCN Clinical Practice Guidelines in oncology for genetics\/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate cancer, version 2.2025. November 7, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1545"},{"key":"10.1016\/j.gim.2024.101243_bib115","unstructured":"Gupta S, Weiss JM, Axell L, et al. NCCN Clinical Practice Guidelines in oncology for genetics\/familial high-risk assessment: Colorectal, endometrial, and gastric, version 3.2024. October 31, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1544"},{"issue":"10290","key":"10.1016\/j.gim.2024.101243_bib116","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib117","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jmg-2022-108898","article-title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2","volume":"60","author":"Hanson","year":"2023","journal-title":"J\u00a0Med Genet"},{"issue":"3","key":"10.1016\/j.gim.2024.101243_bib118","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/cells11030539","article-title":"Hereditary ovarian carcinoma: cancer pathogenesis looking beyond BRCA1 and BRCA2","volume":"11","author":"Samuel","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.gim.2024.101243_bib119","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/1535-7163.MCT-19-0208","article-title":"ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications","volume":"18","author":"Armstrong","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10.1016\/j.gim.2024.101243_bib120","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib121","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.gim.2024.101243_bib122","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.gim.2024.101243_bib123","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib124","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.gim.2024.101243_bib125","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1056\/NEJMc2023199","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"383","author":"Mutetwa","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.gim.2024.101243_bib126","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.gim.2024.101243_bib127","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib128","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41598-019-39525-3","article-title":"Prognostic impact of ATM mutations in patients with metastatic colorectal cancer","volume":"9","author":"Randon","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.gim.2024.101243_bib129","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"issue":"28","key":"10.1016\/j.gim.2024.101243_bib130","doi-asserted-by":"crossref","first-page":"19817","DOI":"10.18632\/oncotarget.24865","article-title":"Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer","volume":"9","author":"Kondo","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","article-title":"Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials","volume":"7","author":"Javle","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib132","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced prostate cancer with ATM loss: PARP and ATR inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.gim.2024.101243_bib133","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.06.010","article-title":"The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma","volume":"432","author":"Shi","year":"2018","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib134","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.gim.2024.101243_bib135","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/bjc.2011.266","article-title":"Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours","volume":"105","author":"Reiman","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib136","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.17736","article-title":"The incidence and type of cancer in patients with ataxia-telangiectasia via a retrospective single-centre study","volume":"194","author":"Bakhtiar","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib137","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","article-title":"Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies","volume":"33","author":"Suarez","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib138","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/bjc.2011.534","article-title":"Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia","volume":"106","author":"Byrd","year":"2012","journal-title":"Br J Cancer"},{"issue":"298","key":"10.1016\/j.gim.2024.101243_bib139","first-page":"169","article-title":"Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals","volume":"82","author":"Woods","year":"1992","journal-title":"Q\u00a0J Med"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1651-2227.1967.tb15424.x","article-title":"Ovarian changes in ataxia telangiectasia","volume":"56","author":"Miller","year":"1967","journal-title":"Acta Paediatr Scand"},{"issue":"6","key":"10.1016\/j.gim.2024.101243_bib141","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00210809","article-title":"Unusual features in the inheritance of ataxia telangiectasia","volume":"84","author":"Woods","year":"1990","journal-title":"Hum Genet"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib142","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-4608(91)90164-P","article-title":"The cytogenetics of ataxia telangiectasia","volume":"56","author":"Kojis","year":"1991","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"10.1016\/j.gim.2024.101243_bib143","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/practneurol-2019-002253","article-title":"Ataxia telangiectasia: what the neurologist needs to know","volume":"20","author":"Tiet","year":"2020","journal-title":"Pract Neurol"},{"key":"10.1016\/j.gim.2024.101243_bib144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clim.2017.01.009","article-title":"Ataxia-telangiectasia: immunodeficiency and survival","volume":"178","author":"van Os","year":"2017","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib145","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s10875-021-01090-8","article-title":"Simple measurement of IgA predicts immunity and mortality in ataxia-telangiectasia","volume":"41","author":"Zielen","year":"2021","journal-title":"J Clin Immunol"},{"issue":"7","key":"10.1016\/j.gim.2024.101243_bib146","first-page":"610","article-title":"Survival probability in ataxia telangiectasia","volume":"91","author":"Crawford","year":"2006","journal-title":"Arch Dis\u00a0Child"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib147","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ana.25394","article-title":"Genotype, extrapyramidal features, and severity of variant ataxia-telangiectasia","volume":"85","author":"Schon","year":"2019","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.gim.2024.101243_bib148","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41436-021-01203-z","article-title":"Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Gregg","year":"2021","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.gim.2024.101243_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100866","article-title":"ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Miller","year":"2023","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101243_bib151","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10689-022-00293-1","article-title":"Preimplantation genetic testing in patients with genetic susceptibility to cancer","volume":"22","author":"Villy","year":"2023","journal-title":"Fam Cancer"},{"issue":"13","key":"10.1016\/j.gim.2024.101243_bib152","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/1471-0528.17571","article-title":"Prenatal and pre-implantation genetic testing for monogenic disorders for germline cancer susceptibility gene variants: UK joint consensus guidance","volume":"130","author":"Wafik","year":"2023","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.gim.2024.101243_bib153","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","article-title":"BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface","volume":"110","author":"Lee","year":"2014","journal-title":"Br J Cancer"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360024001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360024001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:05:07Z","timestamp":1767229507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360024001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1098360024001771"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2024.101243","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2024.101243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101243"}}